Tearing down the walls: FDA approves next generation sequencing (NGS) assays for actionable cancer genomic aberrations

The United States Food and Drug Administration (FDA) recently approved the clinical use of two comprehensive ‘mid-size’ Next Generation Sequencing (NGS) panels calling actionable genomic aberrations in cancer. This is the first endorsement, by a regulatory body, of a new standard of care in oncology...

Descripción completa

Detalles Bibliográficos
Autores principales: Allegretti, Matteo, Fabi, Alessandra, Buglioni, Simonetta, Martayan, Aline, Conti, Laura, Pescarmona, Edoardo, Ciliberto, Gennaro, Giacomini, Patrizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5838869/
https://www.ncbi.nlm.nih.gov/pubmed/29506529
http://dx.doi.org/10.1186/s13046-018-0702-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5838869/
https://www.ncbi.nlm.nih.gov/pubmed/29506529
http://dx.doi.org/10.1186/s13046-018-0702-x

Ejemplares similares